| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ORIGINAL RESEARCH COMMUNICATION |
1 From the Clinical Trial Service Unit, University of Oxford, Oxford, United Kingdom (RC, PS, SL, and RC), and the Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom (CF). (The names of the authors whose initials are listed here are given in the acknowledgments section at the end of the article.)
Background: Dietary supplementation with B vitamins that lower blood homocysteine concentrations is expected to reduce cardiovascular disease risk, but there has been uncertainty about the optimum regimen to use for this purpose.
Objective: The objectives were to ascertain the lowest dose of folic acid associated with the maximum reduction in homocysteine concentrations and to determine the additional relevance of vitamins B-12 and B-6.
Design: A meta-analysis of 25 randomized controlled trials involving individual data on 2596 subjects assessed the effect on plasma homocysteine concentrations of different doses of folic acid and of the addition of vitamins B-12 and B-6.
Results: The proportional reductions in plasma homocysteine concentrations produced by folic acid were greater at higher homocysteine (P < 0.001) and lower folate (P < 0.001) pretreatment concentrations; they were also greater in women than in men (P < 0.001). After standardization for sex and to pretreatment plasma concentrations of 12 µmol homocysteine/L and 12 nmol folate/L, daily doses of 0.2, 0.4, 0.8, 2.0, and 5.0 mg folic acid were associated with reductions in homocysteine of 13% (95% CI: 10%, 16%), 20% (17%, 22%), 23% (21%, 26%), 23% (20%, 26%), and 25% (22%, 28%), respectively. Vitamin B-12 (
: 0.4 mg/d) produced 7% (95% CI: 4%, 9%) further reduction in homocysteine concentrations, but vitamin B-6 had no significant effect.
Conclusions: Daily doses of 
0.8 mg folic acid are typically required to achieve the maximal reduction in plasma homocysteine concentrations produced by folic acid supplementation. Doses of 0.2 and 0.4 mg are associated with 60% and 90%, respectively, of this maximal effect.
Key Words: Homocysteine • folic acid • randomized trial
Related articles in AJCN:
This article has been cited by other articles:
|
|
 |
|
  C. Antoniades, A. S. Antonopoulos, D. Tousoulis, K. Marinou, and C. Stefanadis Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials Eur. Heart J., January 1, 2009; 30(1): 6 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. P. Almeida, K. McCaul, G. J. Hankey, P. Norman, K. Jamrozik, and L. Flicker Homocysteine and Depression in Later Life Arch Gen Psychiatry, November 1, 2008; 65(11): 1286 - 1294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Clarke and D. A. Bennett B Vitamins for Prevention of Cognitive Decline: Insufficient Evidence to Justify Treatment JAMA, October 15, 2008; 300(15): 1819 - 1821. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Hao, Q.-H. Yang, Z. Li, L. B Bailey, J.-H. Zhu, D. J Hu, B.-L. Zhang, J D. Erickson, L. Zhang, J. Gindler, et al. Folate status and homocysteine response to folic acid doses and withdrawal among young Chinese women in a large-scale randomized double-blind trial Am. J. Clinical Nutrition, August 1, 2008; 88(2): 448 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q.-H. Yang, L. D Botto, M. Gallagher, J. Friedman, C. L Sanders, D. Koontz, S. Nikolova, J D. Erickson, and K. Steinberg Prevalence and effects of gene-gene and gene-nutrient interactions on serum folate and serum total homocysteine concentrations in the United States: findings from the third National Health and Nutrition Examination Survey DNA Bank Am. J. Clinical Nutrition, July 1, 2008; 88(1): 232 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J Moat Plasma total homocysteine: instigator or indicator of cardiovascular disease? Ann Clin Biochem, July 1, 2008; 45(4): 345 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Lonn Homocysteine-Lowering B Vitamin Therapy in Cardiovascular Prevention--Wrong Again? JAMA, May 7, 2008; 299(17): 2086 - 2087. [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Ueland and S. Hustad Homocysteine and Folate Status in an Era of Folic Acid Fortification: Balancing Benefits, Risks, and B-vitamins Clin. Chem., May 1, 2008; 54(5): 779 - 781. [Full Text] [PDF]
|
|
|
|
|
|
C. M. Pfeiffer, J. D. Osterloh, J. Kennedy-Stephenson, M. F. Picciano, E. A. Yetley, J. I. Rader, and C. L. Johnson Trends in Circulating Concentrations of Total Homocysteine among US Adolescents and Adults: Findings from the 1991-1994 and 1999-2004 National Health and Nutrition Examination Surveys Clin. Chem., May 1, 2008; 54(5): 801 - 813. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Larsson, S. Mannisto, M. J. Virtanen, J. Kontto, D. Albanes, and J. Virtamo Folate, Vitamin B6, Vitamin B12, and Methionine Intakes and Risk of Stroke Subtypes in Male Smokers Am. J. Epidemiol., April 15, 2008; 167(8): 954 - 961. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Wallace, M. P Bonham, J. Strain, E. M Duffy, P. J Robson, M. Ward, H. McNulty, P. W Davidson, G. J Myers, C. F Shamlaye, et al. Homocysteine concentration, related B vitamins, and betaine in pregnant women recruited to the Seychelles Child Development Study Am. J. Clinical Nutrition, February 1, 2008; 87(2): 391 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. E. Mann, P. Sheridan, M. J. McQueen, C. Held, J. M. O. Arnold, G. Fodor, S. Yusuf, E. M. Lonn, and on behalf of the HOPE-2 investigators Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study Nephrol. Dial. Transplant., February 1, 2008; 23(2): 645 - 653. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Clarke, J. Birks, E. Nexo, P. M Ueland, J. Schneede, J. Scott, A. Molloy, and J. G. Evans Low vitamin B-12 status and risk of cognitive decline in older adults Am. J. Clinical Nutrition, November 1, 2007; 86(5): 1384 - 1391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Weikert, J. Dierkes, K. Hoffmann, K. Berger, D. Drogan, K. Klipstein-Grobusch, J. Spranger, M. Mohlig, C. Luley, and H. Boeing B Vitamin Plasma Levels and the Risk of Ischemic Stroke and Transient Ischemic Attack in a German Cohort Stroke, November 1, 2007; 38(11): 2912 - 2918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E Chiuve, E. L Giovannucci, S. E Hankinson, S. H Zeisel, L. W Dougherty, W. C Willett, and E. B Rimm The association between betaine and choline intakes and the plasma concentrations of homocysteine in women Am. J. Clinical Nutrition, October 1, 2007; 86(4): 1073 - 1081. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. de Bree, L. A van Mierlo, and R. Draijer Folic acid improves vascular reactivity in humans: a meta-analysis of randomized controlled trials Am. J. Clinical Nutrition, September 1, 2007; 86(3): 610 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chattopadhyay, R. Tamari, S. H. Min, R. Zhao, E. Tsai, and I. D. Goldman Commentary: A Case for Minimizing Folate Supplementation in Clinical Regimens with Pemetrexed Based on the Marked Sensitivity of the Drug to Folate Availability Oncologist, July 1, 2007; 12(7): 808 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Ulrich and J. D. Potter Folate and Cancer--Timing Is Everything JAMA, June 6, 2007; 297(21): 2408 - 2409. [Full Text] [PDF]
|
|
|
|
|
|
P. M. Ueland and R. Clarke Homocysteine and Cardiovascular Risk: Considering the Evidence in the Context of Study Design, Folate Fortification, and Statistical Power Clin. Chem., May 1, 2007; 53(5): 807 - 809. [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. McMahon, C. M. Skeaff, S. M. Williams, and T. J. Green Lowering Homocysteine with B Vitamins Has No Effect on Blood Pressure in Older Adults J. Nutr., May 1, 2007; 137(5): 1183 - 1187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J Green, J. A McMahon, C M. Skeaff, S. M Williams, and S. J Whiting Lowering homocysteine with B vitamins has no effect on biomarkers of bone turnover in older persons: a 2-y randomized controlled trial Am. J. Clinical Nutrition, February 1, 2007; 85(2): 460 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chattopadhyay, R. G. Moran, and I. D. Goldman Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications Mol. Cancer Ther., February 1, 2007; 6(2): 404 - 417. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J.M. de Craen, D. J. Stott, R. G.J. Westendorp, A. Khare, M. Lopez, J. Gogtay, E. P. Quinlivan, J. F. Gregory III, H. Refsum, A. D. Smith, et al. Homocysteine, B vitamins, and cardiovascular disease. N. Engl. J. Med., July 13, 2006; 355(2): 205 - 206. [Full Text] [PDF]
|
|
|
|
|
|
R. Clarke Vitamin B12, folic acid, and the prevention of dementia. N. Engl. J. Med., June 29, 2006; 354(26): 2817 - 2819. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yamada, R. A. Gravel, T. Toraya, and R. G. Matthews Human methionine synthase reductase is a molecular chaperone for human methionine synthase PNAS, June 20, 2006; 103(25): 9476 - 9481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. H. Bonaa, I. Njolstad, P. M. Ueland, H. Schirmer, A. Tverdal, T. Steigen, H. Wang, J. E. Nordrehaug, E. Arnesen, K. Rasmussen, et al. Homocysteine Lowering and Cardiovascular Events after Acute Myocardial Infarction N. Engl. J. Med., April 13, 2006; 354(15): 1578 - 1588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The Heart Outcomes Prevention Evaluation (HOPE) 2 Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease N. Engl. J. Med., April 13, 2006; 354(15): 1567 - 1577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Minerva BMJ, October 29, 2005; 331(7523): 1032 - 1032. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
